Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HRS-1893 Dose level 1 | Experimental | Single oral low dose of HRS-1893 (dose level 1) |
|
| HRS-1893 Dose level 2 | Experimental | Single oral high dose of HRS-1893 (dose level 2) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HRS-1893 | Drug | Single dose of HRS-1893 orally administered |
|
| Measure | Description | Time Frame |
|---|---|---|
| PK profile of HRS-1893 after a single oral (PO) administration | Pharmacokinetics PK Cmax: Plasma Cmax | Day 8 |
| PK profile of HRS-1893 after a single oral (PO) administration | Pharmacokinetics PK AUClast : Plasma AUClast | Day 8 |
| PK profile of HRS-1893 after a single oral (PO) administration | Pharmacokinetics PK AUC0-inf: Plasma AUC0-inf | Day 8 |
| PK profile of HRS-1893 after a single oral (PO) administration | Pharmacokinetics PK Tmax :Plasma Tmax | Day 8 |
| PK profile of HRS-1893 after a single oral (PO) administration | Pharmacokinetics PK t1/2 : Plasma t1/2 | Day 8 |
| PK profile of HRS-1893 after a single oral (PO) administration | Pharmacokinetics PK CL/F: Plasma CL/F | Day 8 |
| PK profile of HRS-1893 after a single oral (PO) administration | Pharmacokinetics PK Vz/F: Plasma Vz/F | Day 8 |
| Cumulative amount of drug excreted in urine of HRS-1893 after a single oral administration | Cumulative amount of drug excreted in urine (Ae,ur) |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events | Number of participants with Adverse events and Serious adverse events | Day 8 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Linear Clinical Research | Nedlands | Western Australia | 6009 | Australia |
Not provided
| ID | Term |
|---|---|
| D002312 | Cardiomyopathy, Hypertrophic |
| ID | Term |
|---|---|
| D009202 | Cardiomyopathies |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001020 | Aortic Stenosis, Subvalvular |
Not provided
Not provided
HRS-1893 Oral dosage only
Not provided
Not provided
Not provided
Not provided
| Day 8 |
| Cumulative percentage of dose recovered in urine of HRS-1893 after a single oral administration: | Cumulative percentage of dose recovered in urine (%Ae,ur) | Day 8 |
| Renal clearance of HRS-1893 after a single oral administration | Renal clearance (CLr) | Day 8 |
| D001024 |
| Aortic Valve Stenosis |
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |